FaAP – Fair and Affordable Pricing
Scope of the Project
Visegrad Group (V4) Poland, Slovakia, Czech Republic, Hungary
Objective of the Project
Improving and facilitating access to effective and safe health technologies while maintaining cost-effectiveness.
Developing a system to facilitate international cooperation and enable joint price negotiations on the reimbursement of medicinal products.
Description of the Project
On 3 March 2017, during the meeting of the Ministers of Health of the V4 Group countries as well as Croatia and Lithuania, a Memorandum of Understanding on cooperation in the field of fair and affordable pricing of medicinal products (MoU) was signed. It is a political declaration setting out the basic framework and objectives of the FaAP project.
As specified in the document, a Coordination Committee composed of up to five experts per country was established. Poland, Hungary, Slovakia, Croatia and Lithuania joined the Memorandum, followed shortly afterwards by Slovenia.
The main objective of the Memorandum is cooperation in the area of medicine pricing, which will translate into increased availability of affordable medicines. However, a particularly important aspect of the project is exchanging information and experiences concerning, i.a. good practices in the field of the pricing policy, health technology assessment, but also data from processes carried out in particular countries.
In March 2019, the Memorandum of Understanding expired, and therefore, on 15 May 2019 in Warsaw, the Ministers of Health: of Poland, Czech Republic, Slovakia, Hungary and Latvia signed the second Memorandum, which is based on the first document and, taking into account the experience of the last two years of cooperation, updates the project outline and objectives.
Source: https://www.gov.pl/web/zdrowie/podpisanie-memorandum-o-wspolpracy-w-dziedzinie-uczciwych-i-przystepnych-cen-lekow (made available under the following licence: Creative Commons Uznanie Autorstwa 3.0 Polska).
As part of the FaAP, on 11-12 July 2019 the Agency for Health Technology Assessment and Tariff System, initiated the first joint workshop, during which we hosted delegations from all signatories to the Memorandum.
During the two days of the workshop, participants had the opportunity to learn about the reimbursement process practice thanks to organised and moderated workshop meetings with:
- the Praesidium of the Transparency Council;
- clinical leaders, i.e. National Consultants in haematology, neurology and clinical oncology;
- independent experts on the healthcare system;
- the Praesidium of the Economic Committee of the Ministry of Health;
- the directors of Medicine Policy and Pharmacy of the Ministry of Health.
*Ladies and Gentlemen
We inform you that the materials and results of the discussions posted on the Agency’s website are the result of the conceptual work and analytical process carried out by the team of the Agency for Health Technology Assessment and Tariff System based on the EBM paradigm, including: search, selection, synthesis and interpretation of scientific evidence, or the data analysis carried out .
In connection with the above, we would like to inform you that the use of analytical material or the results of the discussion, in accordance with good practice, should be accompanied by information on the source in the form: [title of presentation / report], AOTMiT, Warsaw, June 2021]